NCT01995058Phase 2Terminated

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Study sponsor: Exelixis

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2014-11Actual
Enrollment · participants54Actual
Source updated2026-01-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Radiographic progression free survival (PFS). After: Measure: Radiographic Progression Free Survival (PFS).

Check registry source